154 related articles for article (PubMed ID: 38529375)
1. Case report: A case of metastatic BRAFV600-mutated melanoma with heart failure treated with immune checkpoint inhibitors and BRAF/MEK inhibitors.
Nishizawa A; Kawakami M; Kitahara Y
Front Oncol; 2024; 14():1366532. PubMed ID: 38529375
[TBL] [Abstract][Full Text] [Related]
2. Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors.
Arangalage D; Degrauwe N; Michielin O; Monney P; Özdemir BC
Cancer Treat Rev; 2021 Nov; 100():102282. PubMed ID: 34438238
[TBL] [Abstract][Full Text] [Related]
3. A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma
Tarhini AA; Toor K; Chan K; McDermott DF; Mohr P; Larkin J; Hodi FS; Lee CH; Rizzo JI; Johnson H; Moshyk A; Rao S; Kotapati S; Atkins MB
ESMO Open; 2021 Apr; 6(2):100050. PubMed ID: 33556898
[TBL] [Abstract][Full Text] [Related]
4. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
5. Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab.
Moser JC; Chen D; Hu-Lieskovan S; Grossmann KF; Patel S; Colonna SV; Ying J; Hyngstrom JR
Cancer Med; 2019 Dec; 8(18):7637-7643. PubMed ID: 31677253
[TBL] [Abstract][Full Text] [Related]
6. First-line immunotherapy versus targeted therapy in patients with
Pavlick AC; Zhao R; Lee CH; Ritchings C; Rao S
Future Oncol; 2021 Feb; 17(6):689-699. PubMed ID: 33084375
[No Abstract] [Full Text] [Related]
7. Clinical Case of the Month: A 57-Year-Old Man with an Axillary Mass.
Desai P; Myers A; Boulmay B; Lopez FA
J La State Med Soc; 2017; 169(3):78-82. PubMed ID: 28644156
[TBL] [Abstract][Full Text] [Related]
8. Targeted Therapy in Advanced Melanoma With Rare
Menzer C; Menzies AM; Carlino MS; Reijers I; Groen EJ; Eigentler T; de Groot JWB; van der Veldt AAM; Johnson DB; Meiss F; Schlaak M; Schilling B; Westgeest HM; Gutzmer R; Pföhler C; Meier F; Zimmer L; Suijkerbuijk KPM; Haalck T; Thoms KM; Herbschleb K; Leichsenring J; Menzer A; Kopp-Schneider A; Long GV; Kefford R; Enk A; Blank CU; Hassel JC
J Clin Oncol; 2019 Nov; 37(33):3142-3151. PubMed ID: 31580757
[TBL] [Abstract][Full Text] [Related]
9. Rare immune-related adverse events in a patient with metastatic melanoma: a case report highlighting sarcoidosis-like reactions triggered by immune-checkpoint inhibitors.
Cao Y; Afzal MZ; Gutmann EJ; Shirai K
Melanoma Res; 2024 Feb; 34(1):70-75. PubMed ID: 37830935
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy.
Kuske M; Westphal D; Wehner R; Schmitz M; Beissert S; Praetorius C; Meier F
Pharmacol Res; 2018 Oct; 136():151-159. PubMed ID: 30145328
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006.
Long GV; Arance A; Mortier L; Lorigan P; Blank C; Mohr P; Schachter J; Grob JJ; Lotem M; Middleton MR; Neyns B; Steven N; Ribas A; Walpole E; Carlino MS; Lebbe C; Sznol M; Jensen E; Leiby MA; Ibrahim N; Robert C
Ann Oncol; 2022 Feb; 33(2):204-215. PubMed ID: 34710571
[TBL] [Abstract][Full Text] [Related]
12. Potential immune‑related adverse events during dabrafenib and trametinib treatment: A case series of patients with BRAF V600E melanoma.
Morgese F; Cognigni V; Scortichini L; Ranallo N; Lunerti V; Migliore A; Tronconi F; Berardi R
Mol Clin Oncol; 2023 Jan; 18(1):2. PubMed ID: 36545211
[TBL] [Abstract][Full Text] [Related]
13. Case report: Parsonage-turner syndrome in a melanoma patient treated by BRAF/MEK inhibitors after immune checkpoint inhibitors.
Bonnefin C; Duval F; Rouanet M; Kostine M; Gerard E
Front Oncol; 2023; 13():1268693. PubMed ID: 38192629
[TBL] [Abstract][Full Text] [Related]
14. Plasma proteome alterations by MAPK inhibitors in BRAF
Babačić H; Eriksson H; Pernemalm M
Neoplasia; 2021 Aug; 23(8):783-791. PubMed ID: 34246984
[TBL] [Abstract][Full Text] [Related]
15. BRAF
Finke C; Mohr P
Adv Ther; 2024 May; ():. PubMed ID: 38806993
[TBL] [Abstract][Full Text] [Related]
16. A proof-of-concept study of sequential treatment with the HDAC inhibitor vorinostat following BRAF and MEK inhibitors in BRAFV600mutated melanoma.
Embaby A; Huijberts SCFA; Wang L; Leite de Oliveira R; Rosing H; Nuijen B; Sanders J; Hofland I; van Steenis C; Kluin RJC; Lieftink C; Smith CG; Blank CU; van Thienen JV; Haanen JBAG; Steeghs N; Opdam FL; Beijnen JH; Huitema ADR; Bernards R; Schellens JHM; Wilgenhof S
Clin Cancer Res; 2024 May; ():. PubMed ID: 38739109
[TBL] [Abstract][Full Text] [Related]
17. Triple Combination of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in
Welti M; Dimitriou F; Gutzmer R; Dummer R
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428582
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma.
Pires da Silva I; Zakria D; Ahmed T; Trojanello C; Dimitriou F; Allayous C; Gerard C; Zimmer L; Lo S; Michielin O; Lebbe C; Mangana J; Ascierto PA; Johnson DB; Carlino M; Menzies A; Long G
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35798536
[TBL] [Abstract][Full Text] [Related]
19. Atypical anti-glomerular basement membrane glomerulonephritis in a patient with metastatic melanoma treated with mitogen-activated protein kinase and immune checkpoint inhibitors: a case report.
Kyriazis P; Tiwary A; Freeman J; Landry D; Braden G
J Med Case Rep; 2021 Apr; 15(1):186. PubMed ID: 33810799
[TBL] [Abstract][Full Text] [Related]
20. Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study.
Huynh S; Mortier L; Dutriaux C; Maubec E; Boileau M; Dereure O; Leccia MT; Arnault JP; Brunet-Possenti F; Aubin F; Dreno B; Beylot-Barry M; Lebbe C; Lefevre W; Delyon J
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32585901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
